Stocks · News reference
Canaccord Genuity analyst Edward Nash initiates coverage on Nektar Therapeutics (NASDAQ:NKTR) with a Buy rating and announces Price Target of $153.
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
REZOLVE-AD study met all primary and key secondary endpoints, including EASI-75, EASI-90, Itch NRS, vIGA-AD and BSA, on rezpegaldesleukin 24 µg/kg q2wFirst large, placebo-controlled trial to support T-reg modulation as
Read original at benzingaJP Morgan analyst Jessica Fye reinstates Nektar Therapeutics (NASDAQ:NKTR) with a Neutral and announces $65 price target.
Read original at benzingaNektar Therapeutics (NASDAQ:NKTR) held its second-quarter earnings conference call on Thursday. Below is the complete transcript from the call. This content is powered by Benzinga APIs. For comprehensive financial data
Read original at benzingaFiled: 2026-08-13 AccNo: 0001213900-26-089137 Size: 292 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgar